SOX11 expression promotes in vivo cell migration and specific BM and LN infiltration and engraftment through the activation of CXCR4 and FAK pathways in intravenous MCL xenograft models. Some 10 × 10⁶ SOX11⁺ and SOX11⁻ Z138 MCL cell lines stably transfected to express a luciferase enzyme (Z138CTLuci and Z138KDLuci, respectively) were iv inoculated into SCID mice generating Z138CT and Z138KD mice, respectively. (A) In vivo MCL cell migration toward BM in Z138CT (n = 8) and Z138KD (n = 8) mice 24 hours PI was analyzed using a specific human anti-CD19–PE antibody to determine number of MCL cells in BM by FC. (B) Z138CT mice were randomly assigned and treated every day with 30 mg/kg PF (n = 8) or 10 mg/kg AMD (n = 6) for 28 days and compared with Z138CT and Z138KD control PBS-treated mice (n = 8 each). Graph showing tumor engraftment by quantification of the LBI signals (IntDen) at the indicated days PI. (C) Representative pictures showing MCL engraftment in nodal and extranodal sites 28 days PI by LBI signals of Z138CT mice intraperitoneally (ip) injected with vehicle PBS, PF, or AMD and Z138KD mice injected with vehicle PBS (i). Quantification of the LBI signals (IntDen) in individual Z138CT animals ip injected with vehicle PBS, PF, or AMD and Z138KD mice injected with vehicle PBS at day 28 PI (ii). (D) Graph displaying the number of recovered MCL cells (%) normalized to the total number of cells in PB, BM, and LNs, labeled with a specific human anti-CD19–PE antibody and analyzed by FC. The significance of difference was determined by independent samples Student t test: *P < .05, **P < .01, ***P < .001.